Enter any ticker symbol here to see the live quote & chart tools in action
Your filings are automatically published to your site as they are filed.
Investors don't have to leave your site to see filings.
Once a report has been filed with the SEC it will be available on the website.
Section 16 Filings Only
NOVADEL PHARMA INC filed this 424B3 on 11/01/2011.
Click on link to view section or document
1. Entire Document including Exhibit(s)
2. 424B3 - PROSPECTUS SUPPLEMENT
PAGE: 1 - Prospectus Supplement filed under Rule 424(b)(3)
PAGE: 2 - UNITED STATES
PAGE: 3 - NovaDel Pharma Inc.
PAGE: 4 - PART I. FINANCIAL INFORMATION
PAGE: 5 - NovaDel Pharma Inc.
PAGE: 6 - NovaDel Pharma Inc.
PAGE: 7 - NovaDel Pharma Inc.
PAGE: 8 - NovaDel Pharma Inc.
PAGE: 9 - Note 4 Earnings or Loss Per Share
PAGE: 10 - Derivatives and Hedging.
PAGE: 11 - Derivatives and Hedges
PAGE: 12 - Note 7 Revenue from Licensing Agreements
PAGE: 13 - Note 8 Share-Based Compensation
PAGE: 14 - Note 10 Recent Accounting Pronouncements
PAGE: 15 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations
PAGE: 16 - Duromist
PAGE: 17 - NVD-201
PAGE: 18 - Comparison of the Nine Months ended September 30, 2011 and 2010
PAGE: 19 - Liquidity and Capital Resources
PAGE: 20 - Critical Accounting Policies and Estimates
PAGE: 21 - Recent Accounting Pronouncements
PAGE: 22 - PART II. OTHER INFORMATION
PAGE: 23 - We will require significant capital for product development and commercialization in the near term.
PAGE: 24 - Our technology platform is based solely on our proprietary drug delivery technology. Our ongoing cli
PAGE: 25 - We do not have direct consumer marketing experience.
PAGE: 26 - We face intense competition.
PAGE: 27 - The clinical trial and regulatory approval process for our products is expensive and time consuming,
PAGE: 28 - Our strategy includes entering into collaboration agreements with third parties for certain of our p
PAGE: 29 - If we cannot protect our intellectual property, other companies could use our technology in competit
PAGE: 30 - Even if we obtain patents to protect our products, those patents may not be sufficiently broad and o
PAGE: 31 - Our inability to manage the future growth that we are attempting to achieve could severely harm our
PAGE: 32 - Compliance with changing regulation of corporate governance and public disclosure may result in addi
PAGE: 33 - Provisions of our certificate of incorporation and Delaware law could deter a change of our manageme
PAGE: 34 - The market price of our stock and our earnings may be adversely affected by market volatility.
PAGE: 35 - Penny stock regulations may impose certain restrictions on marketability of our securities.
PAGE: 36 - Shares eligible for future sale may adversely affect the market.
PAGE: 37 - We may incur significant costs from class action litigation due to our expected stock volatility.
PAGE: 38 - Item 6. Exhibits
PAGE: 39 - SIGNATURES
Quote & Chart Package
Basic Stock Chart
Basic Stock Quote
Embedded Quote / Chart
Embedded Full Quote / Chart
Pop Up Quote
You are viewing our Quote and Chart Demo using ticker symbol
© 2004 Stockgroup Media Inc.